PlumX Metrics
Embed PlumX Metrics

Update on the role of quantitative HBsAg and HBeAg monitoring during peginterferon therapy

Current Hepatitis Reports, ISSN: 1540-3416, Vol: 11, Issue: 2, Page: 75-81
2012
  • 0
    Citations
  • 0
    Usage
  • 4
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Article Description

Pegylated Interferon alfa (PEG-IFN) is the only licensed agent that allows a sustained virologic response in a subset group of patients with chronic hepatitis B, both e antigen (HBeAg)-positive and negative, after a finite course of therapy. Despite this major advantage, its use is limited because of its lack of efficacy in a large proportion of patients and a high relapse rate especially in HBeAg-negative patients. Baseline host and viral factors have been largely used to identify candidates for PEG-IFN therapy in the pre-treatment phase, but they have failed to translate into a clear therapeutic choice because of their low predictability. Recently, the use of HBeAg and especially hepatitis B surface antigen (HBsAg) as quantitative serological markers, has led to a revolution in the management of this disease by introducing a new concept of on-treatment prediction of response and stopping rules as early as week 12 of therapy. © 2012 Springer Science+Business Media, LLC.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know